Ranbaxy whistleblower pockets $50M+ in $500M settlement
This article was originally published in Scrip
Executive Summary
The $50 million-plus a former executive at Ranbaxy is walking away with is another reality check for companies that when they engage in wrongdoing, there is likely someone watching and willing to come forward.
You may also be interested in...
FDA To Lift Ban On Ranbaxy Plant; Good News For Sun Compliance Push?
A US FDA ban on Sun Pharma’s Mohali site, a legacy Ranbaxy facility, is set to be lifted, marking a significant uptick in Sun’s compliance efforts and raising hopes of momentum at the Indian firm’s other tainted facilities.
Daiichi Arbitration Case Bares Trail Of Deception At Ranbaxy
Incriminating details in an arbitration order against the former Ranbaxy top brass led by the Singh brothers has put the spotlight back on allegations of misrepresentation of critical information concerning the US Department of Justice (DoJ) and FDA investigations against the Indian company at the time of its takeover by Daiichi Sankyo. The Singh brothers, who have challenged the award, though, have cried foul, questioning the timing of the apparent leak of the "confidential" award ahead of a court hearing.
Golden Week For Daiichi: Damages Due From Ranbaxy Brothers
In what seems like some consolation for Daiichi Sankyo after its disastrous acquisition of Ranbaxy Laboratories and subsequent divestment of the Indian company, arbitration proceedings in Singapore against the Singh brothers of Ranbaxy have gone the Japanese firm's way.